TM-5614 NEW

 
TM5614 , owned by Japanese company Renascience,is a drug that partially inhibits PAI-1.In mice, in addition to being instrumental in proper blood clotting, PAI-1 seems to be involved in hair loss.

Scientists noticed that mice bred to have too much PAI-1 seemed "older" than they should. They were born bald and never grew hair. "They don't quite look right," he added.


While the absence of the protein can cause health problems, the team's work in animals suggests that a reduction in PAI-1 might be beneficial.

In early research in mice bred to have too much PAI-1, Reaserchers noticed that animals that were administered the drug began growing hair. 


Team has higher hopes for the drug's reach beyond the restoration of hair follicles, however. Renascience plans to test TM5614 as a supportive therapy in the treatment of cancer, to be administered in conjunction with standard chemotherapy. The thought is that it may be more effective than current treatments for stimulating the production of new blood cells following chemotherapy.

Application
Renascience has licensed TM5614 to American company Eirion Therapeutics, which plans to develop a topical cream that will be tested for preventing and treating male-pattern baldness.


Side Effects
It's been tested 160 healthy people in Japan, none of whom suffered any serious side-effects.